Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial

被引：21

作者：

Koerkamp, B. Groot ^{[1
]}

Janssen, Q. P. ^{[1
]}

van Dam, J. L. ^{[1
]}

Bonsing, B. A. ^{[2
]}

Bos, H. ^{[3
]}

Bosscha, K. P. ^{[4
]}

Haberkorn, B. C. M. ^{[5
]}

de Hingh, I. H. J. T. ^{[6
]}

Karsten, T. M. ^{[7
]}

Van der Kolk, M. B. ^{[8
]}

Liem, M. S. L. ^{[9
]}

Loosveld, O. J. L. ^{[10
]}

Patijn, G. A. ^{[11
]}

van Santvoort, H. C. M. ^{[12
]}

de Vos-Geelen, J. ^{[13
]}

van der Holt, B. ^{[14
]}

Homs, M. Y. V. ^{[15
]}

van Tienhoven, G. ^{[16
]}

Besselink, M. G. ^{[17
]}

Wilmink, H. W. ^{[18
]}

机构：

[1] Erasmus MC Canc Inst, Surg, Rotterdam, Netherlands

[2] LUMC Leiden Univ Med Ctr, Surg, Leiden, Netherlands

[3] Ziekenhuis Tjongerschans, Internal Med, Heerenveen, Netherlands

[4] Jeroen Bosch Hosp, Surg, Shertogenbosch, Netherlands

[5] Maasstad Ziekenhuis, Internal Med, Rotterdam, Netherlands

[6] Catharina Hosp, Surg, Eindhoven, Netherlands

[7] OLVG Hosp, Surg, Amsterdam, Netherlands

[8] Radboud Univ Nijmegen, Surg, Med Ctr, Nijmegen, Netherlands

[9] Med Spectrum Twente, Surg, Enschede, Netherlands

[10] Amphia Ziekenhuis Locat Molengracht, Dept Med Oncol, Breda, Netherlands

[11] Isala Hosp, Surg, Zwolle, Netherlands

[12] UMC Univ Med Ctr Utrecht, Surg, Utrecht, Netherlands

[13] Maastricht Univ Med Ctr MUMC, Dept Med Oncol, Maastricht, Netherlands

[14] Erasmus MC Canc Inst, Hematol, Rotterdam, Netherlands

[15] Erasmus MC Canc Inst, Med Oncol, Rotterdam, Netherlands

[16] Univ Amsterdam, Radiat Oncol, Amsterdam UMC, Amsterdam, Netherlands

[17] Univ Amsterdam, Surg, Amsterdam UMC, Amsterdam, Netherlands

[18] Univ Amsterdam, Med Oncol, Amsterdam UMC, Amsterdam, Netherlands

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.084

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA83

引用

页码：S1323 / S1323

页数：1

共 50 条

[41] Neoadjuvant FOLFIRINOX and IMRT concurrent with FDR-gemcitabine in patients with borderline resectable pancreatic cancer (BRPC).
Tran, Nguyen H.
Sahai, Vaibhav
Griffith, Kent A.
Nathan, Hari
Kaza, Ravi
Cuneo, Kyle Clifford
Sonnenday, Christopher J.
Cho, Clifford
Lawrence, Theodore Steven
Zalupski, Mark
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[42] Folfirinox versus gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic adenocarcinoma: A propensity matched analysis.
Dhir, Mashaal
Zenati, Mazen S.
Hamad, Ahmad
Singhi, Aatur D.
Bahary, Nathan
Hogg, Melissa Ellen
Zeh, Herbert
Zureikat, Amer H.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[43] Neoadjuvant chemotherapy with gemcitabine-based regimens improves the prognosis of node positive resectable pancreatic head cancer
Tajima, Hidehiro
Ohta, Tetsuo
Okazaki, Mitsuyoshi
Yamaguchi, Takahisa
Ohbatake, Yoshinao
Okamoto, Koichi
Nakanuma, Shinichi
Kinoshita, Jun
Makino, Isamu
Nakamura, Keishi
Miyashita, Tomoharu
Takamura, Hiroyuki
Ninomiya, Itasu
Fushida, Sachio
Nakamura, Hiroyuki
MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (02) : 157 - 166
[44] Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial
Versteijne, Eva
van Eijck, Casper H. J.
Punt, Cornelis J. A.
Suker, Mustafa
Zwinderman, Aeilko H.
Dohmen, Miriam A. C.
Groothuis, Karin B. C.
Busch, Oliver R. C.
Besselink, Marc G. H.
de Hingh, Ignace H. J. T.
ten Tije, Albert J.
Patijn, Gijs A.
Bonsing, Bert A.
de Vos-Geelen, Judith
Klaase, Joost M.
Festen, Sebastiaan
Boerma, Djamila
Erdmann, Joris I.
Molenaar, I. Quintus
van der Harst, Erwin
van der Kolk, Marion B.
Rasch, Coen R. N.
van Tienhoven, Geertjan
TRIALS, 2016, 17
[45] Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma A Phase 2 Clinical Trial
Murphy, Janet E.
Wo, Jennifer Y.
Ryan, David P.
Jiang, Wenqing
Yeap, Beow Y.
Drapek, Lorraine C.
Blaszkowsky, Lawrence S.
Kwak, Eunice L.
Allen, Jill N.
Clark, Jeffrey W.
Faris, Jason E.
Zhu, Andrew X.
Goyal, Lipika
Lillemoe, Keith D.
DeLaney, Thomas F.
Fernandez-del Castillo, Carlos
Ferrone, Cristina R.
Hong, Theodore S.
JAMA ONCOLOGY, 2018, 4 (07) : 963 - 969
[46] Survival Outcomes of Patients With Borderline Resectable and Resectable Pancreatic Adenocarcinoma Treated With Neoadjuvant Short-Course Chemoradiotherapy With Capecitabine-Based vs. Gemcitabine-Based Concurrent Chemotherapy
Neibart, S. S.
Mamidanna, S.
Chundury, A.
Sayan, M.
Alexander, H. R.
August, D.
Berim, L. D.
Boland, P. M.
Grandhi, M. S.
Gulhati, P.
Hochster, H. S.
Kennedy, T. J.
Langan, R. C.
Spencer, K.
Jabbour, S. K.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E64 - E64
[47] Neoadjuvant Chemotherapy Efficacy and Safety in Borderline Resectable Pancreatic Cancer
He, X.
Zheng, Y.
Wang, Jiabao
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 85 : 62 - 66
[48] Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report
Palmarocchi, Maria Celeste
Canger, Ruben Carlo Balzarotti
Saletti, Piercarlo
ONCOLOGY LETTERS, 2017, 13 (06) : 4445 - 4452
[49] Clinicopathologic findings of borderline resectable pancreatic cancer after neoadjuvant chemoradiotherapy
Naito, Yoshiki
Nakayama, Masamichi
Ishikawa, Hiroto
Takahashi, Kenjiro
Hisaka, Toru
Okuda, Koji
Fukahori, Masaru
Ishida, Yusuke
Okabe, Yoshinobu
Mihara, Yutaro
Tanigawa, Masahiko
Akiba, Jun
Torimura, Takuji
Yano, Hirohisa
CANCER RESEARCH, 2018, 78 (13)
[50] Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
Cloyd, Jordan M.
Heh, Victor
Pawlik, Timothy M.
Ejaz, Aslam
Dillhoff, Mary
Tsung, Allan
Williams, Terence
Abushahin, Laith
Bridges, John F. P.
Santry, Heena
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)

← 1 2 3 4 5 →